Spero Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.04 | -$0.04 | -$0.04 |
| Q2 2024 | 1 | -$0.38 | -$0.38 | -$0.38 |
| Q3 2024 | 2 | -$0.58 | -$0.40 | -$0.50 |
| Q4 2024 | 1 | -$0.52 | -$0.52 | -$0.52 |
| Q1 2025 | 1 | -$0.49 | -$0.49 | -$0.49 |
| Q2 2025 | 1 | -$0.49 | -$0.49 | -$0.49 |
| Q3 2025 | 1 | -$0.47 | -$0.47 | -$0.47 |
| Q4 2025 | 1 | -$0.34 | -$0.34 | -$0.34 |
Spero Therapeutics, Inc. Earnings Date And Information
Spero Therapeutics, Inc. last posted its earnings results on Monday, August 5th, 2024. The company reported $-0.33 earnings per share for the quarter, topping analysts' consensus estimates of $-0.35 by $0.02. The company had revenue of 6.02 M for the quarter and had revenue of 96.74 M for the year. Spero Therapeutics, Inc. has generated $0 earnings per share over the last year ($0.43 diluted earnings per share) and currently has a price-to-earnings ratio of 4.1. Spero Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, November 10th, 2024 based on prior year's report dates.
Spero Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/05/2024 | Q2 2024 | -$0.35 | -$0.33 | 0.02 | $4.90 M | $6.02 M |
| 05/15/2024 | Q1 2024 | -$0.07 | -$0.24 | -0.17 | $4.20 M | |
| 03/13/2024 | Q4 2023 | -$0.10 | $0.97 | 1.07 | $71.83 M | |
| 11/13/2023 | Q3 2023 | -$0.15 | -$0.06 | 0.09 | $14.97 M | $25.47 M |
| 08/10/2023 | Q2 2023 | -$0.29 | -$0.23 | 0.06 | $1.08 M | $788,000 |
| 05/11/2023 | Q1 2023 | -$0.35 | -$0.23 | 0.12 | $740,000 | |
| 03/30/2023 | Q4 2022 | $0.55 | $46.30 M | |||
| 11/14/2022 | Q3 2022 | -$0.34 | -$0.33 | 0.01 | $5.42 M | $1.08 M |
| 08/10/2022 | Q2 2022 | -$0.88 | -$0.87 | 0.01 | $1.43 M | $896,000 |
| 05/16/2022 | Q1 2022 | -$1.09 | $247,000 | |||
| 03/31/2022 | Q4 2021 | -$0.80 | -$0.91 | -0.11 | $2.74 M | |
| 11/10/2021 | Q3 2021 | -$0.70 | -$0.70 | 0 | $4.47 M | $3.06 M |
| 08/05/2021 | Q2 2021 | -$0.77 | -$0.63 | 0.14 | $4.53 M | $5.15 M |
| 05/06/2021 | Q1 2021 | -$0.61 | -$0.66 | -0.05 | $7.30 M | |
| 03/11/2021 | Q4 2020 | -$0.77 | -$0.68 | 0.09 | $1.91 M | |
| 11/05/2020 | Q3 2020 | -$0.91 | -$0.86 | 0.05 | $3.01 M | $4.00 M |
| 08/06/2020 | Q2 2020 | -$1.17 | -$0.85 | 0.32 | $3.31 M | $1.73 M |
| 05/08/2020 | Q1 2020 | -$1.35 | -$1.19 | 0.16 | $169,000 | |
| 03/16/2020 | Q4 2019 | -$1.09 | -$1.32 | -0.23 | $696,000 | |
| 11/04/2019 | Q3 2019 | -$0.80 | -$0.95 | -0.15 | $2.45 M | $172,000 |
Spero Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Spero Therapeutics, Inc.'s earnings date?
Spero Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Sunday, November 10th, 2024 based off last year's report dates.
-
Did Spero Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Spero Therapeutics, Inc. (:SPRO) reported $-0.33 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.35 by $0.02.
-
How can I listen to Spero Therapeutics, Inc.'s earnings conference call?
The conference call for Spero Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Spero Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Spero Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Spero Therapeutics, Inc. generate each year?
Spero Therapeutics, Inc. (:SPRO) has a recorded annual revenue of $96.74 M.
-
How much profit does Spero Therapeutics, Inc. generate each year?
Spero Therapeutics, Inc. (:SPRO) has a recorded net income of $96.74 M. Spero Therapeutics, Inc. has generated $0.43 earnings per share over the last four quarters.
-
What is Spero Therapeutics, Inc.'s price-to-earnings ratio?
Spero Therapeutics, Inc. (:SPRO) has a price-to-earnings ratio of 4.1 and price/earnings-to-growth ratio is -0.18.
